EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study

Govind Kallee iD, Gérard Milano, Florence Duffaud, Laetitia Dahan, Joseph Ciccolini iD

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70035 ↗

At a glance

Journal article in Fundamental & Clinical Pharmacology, 2025. Written by Govind Kallee and 4 co-authors. Institution: PRISM, Biogenopôle La Timone University Hospital of Marseille, Marseille, France. Major MEDLINE topics: Fluorouracil, Dihydrouracil Dehydrogenase (NADP), Antimetabolites, Antineoplastic, Neoplasms. Cited 7 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Anticancer drug 5FU is extensively metabolized by dihydropyrimidine dehydrogenase (DPD), an enzyme with high interindividual variability. Poor metabolizer (PM, i.e., DPD deficient) patients are at risk of life‐threatening toxicities. Whether ultra‐rapid metabolizer (UM) status could conversely compromise 5FU efficacy remains to be investigated.

Methods

In this real‐world study, 352 adult patients treated with a 5FU‐containing regimen were screened. Patients were classified as normal (extensive metabolizer, EM), PM, or UM on DPD function based upon baseline plasma uracil monitoring. The impact of DPD status on efficacy and safety endpoints was investigated.

Results

Patients were categorized on DPD as UM (11.9%), EM (75.9%), and PM (12.2%). The response rate was 54.5%, with median PFS and OS of 13.9 and 19 months, respectively. PM patients were treated with an average 13% lower 5FU starting dose. There was no statistical difference in efficacy between UM and other patients. Severe toxicities were observed in less than 5% of patients, an incidence significantly lower than commonly reported with 5FU‐containing regimen and was comparable between UM, EM, and PM patients. Our observations suggest that UM status is not associated with the lack of efficacy of 5FU. In addition, upfront DPD testing with adaptive dosing helps to reduce the incidence of severe toxicities, as PM patients on reduced doses did not have more severe toxicities than other patients treated with standard doses, while exhibiting similar efficacy in terms of response rate and survival.

Conclusion

When upfront DPD screening with adaptive dosing is performed, no difference is observed between UM, EM, and PM patients in terms of efficacy and safety. Trial Registration #PADSA3GKW7

Subjects

MeSH terms (MEDLINE)

FluorouracilDihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticNeoplasmsDihydropyrimidine Dehydrogenase DeficiencyHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overTreatment Outcome

Author keywords

5FUDPDefficacysafety

Substances

FluorouracilDihydrouracil Dehydrogenase (NADP)Antimetabolites, Antineoplastic

Authors and institutions

  • PRISM, Biogenopôle La Timone University Hospital of Marseille, Marseille, France.
  • COMPO, Inserm U1068 CRCM, Marseille, France.
  • Centre Antoine Lacassagne, Nice, France.
  • Medical Oncology, La Timone University Hospital of Marseille, Marseille, France.
  • Digestive Oncology, La Timone University Hospital of Marseille, Marseille, France.

ORCID profiles: Govind Kallee, Joseph Ciccolini

Cite

APA

Kallee, G., Milano, G., Duffaud, F., Dahan, L., & Ciccolini, J. (2025). DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70035

Vancouver

Kallee G, Milano G, Duffaud F, Dahan L, Ciccolini J. DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70035

BibTeX
@article{Kallee2025,
  author = {Kallee, Govind and Milano, Gérard and Duffaud, Florence and Dahan, Laetitia and Ciccolini, Joseph},
  title = {DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70035}
}
Start for free →